nodes	percent_of_prediction	percent_of_DWPC	metapath
Eprosartan—ABCC2—Ethinyl Estradiol—prostate cancer	0.119	0.201	CbGbCtD
Eprosartan—ABCC2—Conjugated Estrogens—prostate cancer	0.0876	0.148	CbGbCtD
Eprosartan—CYP2C9—Bicalutamide—prostate cancer	0.0751	0.127	CbGbCtD
Eprosartan—CYP2C9—Nilutamide—prostate cancer	0.0751	0.127	CbGbCtD
Eprosartan—ABCC2—Etoposide—prostate cancer	0.0502	0.0848	CbGbCtD
Eprosartan—ABCC2—Docetaxel—prostate cancer	0.046	0.0776	CbGbCtD
Eprosartan—CYP2C9—Estrone—prostate cancer	0.045	0.0759	CbGbCtD
Eprosartan—ABCC2—Doxorubicin—prostate cancer	0.0343	0.0578	CbGbCtD
Eprosartan—CYP2C9—Capecitabine—prostate cancer	0.0341	0.0575	CbGbCtD
Eprosartan—CYP2C9—Estradiol—prostate cancer	0.0258	0.0436	CbGbCtD
Eprosartan—Losartan—UGT2B17—prostate cancer	0.00604	0.767	CrCbGaD
Eprosartan—CYP2C9—urine—prostate cancer	0.0022	0.214	CbGeAlD
Eprosartan—AGTR1—prostate gland—prostate cancer	0.00164	0.159	CbGeAlD
Eprosartan—AGTR1—epithelium—prostate cancer	0.00121	0.117	CbGeAlD
Eprosartan—ABCC2—prostate gland—prostate cancer	0.00119	0.115	CbGeAlD
Eprosartan—AGTR1—renal system—prostate cancer	0.00112	0.108	CbGeAlD
Eprosartan—ABCC2—renal system—prostate cancer	0.00081	0.0784	CbGeAlD
Eprosartan—AGTR1—testis—prostate cancer	0.000724	0.0701	CbGeAlD
Eprosartan—Losartan—CYP3A5—prostate cancer	0.000602	0.0766	CrCbGaD
Eprosartan—Losartan—ACE—prostate cancer	0.000555	0.0706	CrCbGaD
Eprosartan—AGTR1—lymph node—prostate cancer	0.000525	0.0508	CbGeAlD
Eprosartan—ABCC2—testis—prostate cancer	0.000523	0.0507	CbGeAlD
Eprosartan—Losartan—CYP2C19—prostate cancer	0.00041	0.0521	CrCbGaD
Eprosartan—ABCC2—lymph node—prostate cancer	0.000379	0.0367	CbGeAlD
Eprosartan—Losartan—CYP3A4—prostate cancer	0.000261	0.0331	CrCbGaD
Eprosartan—Myalgia—Capecitabine—prostate cancer	8.74e-05	0.000302	CcSEcCtD
Eprosartan—Arthralgia—Capecitabine—prostate cancer	8.74e-05	0.000302	CcSEcCtD
Eprosartan—Chest pain—Capecitabine—prostate cancer	8.74e-05	0.000302	CcSEcCtD
Eprosartan—Haematuria—Epirubicin—prostate cancer	8.72e-05	0.000301	CcSEcCtD
Eprosartan—Anxiety—Capecitabine—prostate cancer	8.71e-05	0.000301	CcSEcCtD
Eprosartan—Discomfort—Capecitabine—prostate cancer	8.63e-05	0.000298	CcSEcCtD
Eprosartan—Epistaxis—Epirubicin—prostate cancer	8.63e-05	0.000298	CcSEcCtD
Eprosartan—Sinusitis—Epirubicin—prostate cancer	8.58e-05	0.000297	CcSEcCtD
Eprosartan—Feeling abnormal—Etoposide—prostate cancer	8.58e-05	0.000296	CcSEcCtD
Eprosartan—Hyperglycaemia—Doxorubicin—prostate cancer	8.56e-05	0.000296	CcSEcCtD
Eprosartan—Diarrhoea—Mitoxantrone—prostate cancer	8.56e-05	0.000296	CcSEcCtD
Eprosartan—Dry mouth—Capecitabine—prostate cancer	8.54e-05	0.000295	CcSEcCtD
Eprosartan—Vomiting—Estradiol—prostate cancer	8.54e-05	0.000295	CcSEcCtD
Eprosartan—Gastrointestinal pain—Etoposide—prostate cancer	8.51e-05	0.000294	CcSEcCtD
Eprosartan—Shock—Docetaxel—prostate cancer	8.51e-05	0.000294	CcSEcCtD
Eprosartan—Ill-defined disorder—Prednisone—prostate cancer	8.48e-05	0.000293	CcSEcCtD
Eprosartan—Thrombocytopenia—Docetaxel—prostate cancer	8.47e-05	0.000293	CcSEcCtD
Eprosartan—Rash—Estradiol—prostate cancer	8.47e-05	0.000293	CcSEcCtD
Eprosartan—Dermatitis—Estradiol—prostate cancer	8.46e-05	0.000292	CcSEcCtD
Eprosartan—Tachycardia—Docetaxel—prostate cancer	8.44e-05	0.000292	CcSEcCtD
Eprosartan—Headache—Estradiol—prostate cancer	8.41e-05	0.000291	CcSEcCtD
Eprosartan—Bradycardia—Epirubicin—prostate cancer	8.36e-05	0.000289	CcSEcCtD
Eprosartan—Angioedema—Prednisone—prostate cancer	8.35e-05	0.000289	CcSEcCtD
Eprosartan—Renal failure—Doxorubicin—prostate cancer	8.32e-05	0.000288	CcSEcCtD
Eprosartan—Neuropathy peripheral—Doxorubicin—prostate cancer	8.3e-05	0.000287	CcSEcCtD
Eprosartan—Urticaria—Etoposide—prostate cancer	8.27e-05	0.000286	CcSEcCtD
Eprosartan—Anorexia—Docetaxel—prostate cancer	8.24e-05	0.000285	CcSEcCtD
Eprosartan—Malaise—Prednisone—prostate cancer	8.24e-05	0.000285	CcSEcCtD
Eprosartan—Shock—Capecitabine—prostate cancer	8.24e-05	0.000285	CcSEcCtD
Eprosartan—Rhinitis—Epirubicin—prostate cancer	8.23e-05	0.000285	CcSEcCtD
Eprosartan—Abdominal pain—Etoposide—prostate cancer	8.23e-05	0.000284	CcSEcCtD
Eprosartan—Body temperature increased—Etoposide—prostate cancer	8.23e-05	0.000284	CcSEcCtD
Eprosartan—Urinary tract infection—Doxorubicin—prostate cancer	8.23e-05	0.000284	CcSEcCtD
Eprosartan—Conjunctivitis—Doxorubicin—prostate cancer	8.23e-05	0.000284	CcSEcCtD
Eprosartan—Vertigo—Prednisone—prostate cancer	8.21e-05	0.000284	CcSEcCtD
Eprosartan—Thrombocytopenia—Capecitabine—prostate cancer	8.2e-05	0.000283	CcSEcCtD
Eprosartan—Syncope—Prednisone—prostate cancer	8.2e-05	0.000283	CcSEcCtD
Eprosartan—Tachycardia—Capecitabine—prostate cancer	8.17e-05	0.000282	CcSEcCtD
Eprosartan—Pharyngitis—Epirubicin—prostate cancer	8.15e-05	0.000282	CcSEcCtD
Eprosartan—Hyperhidrosis—Capecitabine—prostate cancer	8.1e-05	0.00028	CcSEcCtD
Eprosartan—Oedema peripheral—Epirubicin—prostate cancer	8.09e-05	0.00028	CcSEcCtD
Eprosartan—Hypotension—Docetaxel—prostate cancer	8.08e-05	0.000279	CcSEcCtD
Eprosartan—Haematuria—Doxorubicin—prostate cancer	8.07e-05	0.000279	CcSEcCtD
Eprosartan—Loss of consciousness—Prednisone—prostate cancer	8.03e-05	0.000278	CcSEcCtD
Eprosartan—Epistaxis—Doxorubicin—prostate cancer	7.98e-05	0.000276	CcSEcCtD
Eprosartan—Anorexia—Capecitabine—prostate cancer	7.98e-05	0.000276	CcSEcCtD
Eprosartan—Nausea—Estradiol—prostate cancer	7.98e-05	0.000276	CcSEcCtD
Eprosartan—Vomiting—Mitoxantrone—prostate cancer	7.96e-05	0.000275	CcSEcCtD
Eprosartan—Sinusitis—Doxorubicin—prostate cancer	7.94e-05	0.000274	CcSEcCtD
Eprosartan—Visual impairment—Epirubicin—prostate cancer	7.91e-05	0.000274	CcSEcCtD
Eprosartan—Rash—Mitoxantrone—prostate cancer	7.89e-05	0.000273	CcSEcCtD
Eprosartan—Dermatitis—Mitoxantrone—prostate cancer	7.88e-05	0.000272	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Docetaxel—prostate cancer	7.88e-05	0.000272	CcSEcCtD
Eprosartan—Headache—Mitoxantrone—prostate cancer	7.84e-05	0.000271	CcSEcCtD
Eprosartan—Hypotension—Capecitabine—prostate cancer	7.82e-05	0.00027	CcSEcCtD
Eprosartan—Insomnia—Docetaxel—prostate cancer	7.82e-05	0.00027	CcSEcCtD
Eprosartan—Myalgia—Prednisone—prostate cancer	7.78e-05	0.000269	CcSEcCtD
Eprosartan—Arthralgia—Prednisone—prostate cancer	7.78e-05	0.000269	CcSEcCtD
Eprosartan—Paraesthesia—Docetaxel—prostate cancer	7.77e-05	0.000268	CcSEcCtD
Eprosartan—Anxiety—Prednisone—prostate cancer	7.75e-05	0.000268	CcSEcCtD
Eprosartan—Bradycardia—Doxorubicin—prostate cancer	7.73e-05	0.000267	CcSEcCtD
Eprosartan—Dyspnoea—Docetaxel—prostate cancer	7.71e-05	0.000267	CcSEcCtD
Eprosartan—Somnolence—Docetaxel—prostate cancer	7.69e-05	0.000266	CcSEcCtD
Eprosartan—Discomfort—Prednisone—prostate cancer	7.69e-05	0.000266	CcSEcCtD
Eprosartan—Hypersensitivity—Etoposide—prostate cancer	7.67e-05	0.000265	CcSEcCtD
Eprosartan—Tinnitus—Epirubicin—prostate cancer	7.66e-05	0.000265	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Capecitabine—prostate cancer	7.63e-05	0.000264	CcSEcCtD
Eprosartan—Rhinitis—Doxorubicin—prostate cancer	7.62e-05	0.000263	CcSEcCtD
Eprosartan—Dyspepsia—Docetaxel—prostate cancer	7.61e-05	0.000263	CcSEcCtD
Eprosartan—Insomnia—Capecitabine—prostate cancer	7.57e-05	0.000262	CcSEcCtD
Eprosartan—Pharyngitis—Doxorubicin—prostate cancer	7.54e-05	0.000261	CcSEcCtD
Eprosartan—Paraesthesia—Capecitabine—prostate cancer	7.52e-05	0.00026	CcSEcCtD
Eprosartan—Decreased appetite—Docetaxel—prostate cancer	7.52e-05	0.00026	CcSEcCtD
Eprosartan—Oedema peripheral—Doxorubicin—prostate cancer	7.48e-05	0.000259	CcSEcCtD
Eprosartan—Asthenia—Etoposide—prostate cancer	7.47e-05	0.000258	CcSEcCtD
Eprosartan—Dyspnoea—Capecitabine—prostate cancer	7.47e-05	0.000258	CcSEcCtD
Eprosartan—Fatigue—Docetaxel—prostate cancer	7.46e-05	0.000258	CcSEcCtD
Eprosartan—Nausea—Mitoxantrone—prostate cancer	7.43e-05	0.000257	CcSEcCtD
Eprosartan—Pain—Docetaxel—prostate cancer	7.4e-05	0.000256	CcSEcCtD
Eprosartan—Constipation—Docetaxel—prostate cancer	7.4e-05	0.000256	CcSEcCtD
Eprosartan—Dyspepsia—Capecitabine—prostate cancer	7.37e-05	0.000255	CcSEcCtD
Eprosartan—Chills—Epirubicin—prostate cancer	7.37e-05	0.000255	CcSEcCtD
Eprosartan—Pruritus—Etoposide—prostate cancer	7.36e-05	0.000255	CcSEcCtD
Eprosartan—Shock—Prednisone—prostate cancer	7.34e-05	0.000254	CcSEcCtD
Eprosartan—Visual impairment—Doxorubicin—prostate cancer	7.32e-05	0.000253	CcSEcCtD
Eprosartan—Tachycardia—Prednisone—prostate cancer	7.28e-05	0.000252	CcSEcCtD
Eprosartan—Decreased appetite—Capecitabine—prostate cancer	7.28e-05	0.000252	CcSEcCtD
Eprosartan—Fatigue—Capecitabine—prostate cancer	7.22e-05	0.00025	CcSEcCtD
Eprosartan—Hyperhidrosis—Prednisone—prostate cancer	7.21e-05	0.000249	CcSEcCtD
Eprosartan—Pain—Capecitabine—prostate cancer	7.16e-05	0.000248	CcSEcCtD
Eprosartan—Constipation—Capecitabine—prostate cancer	7.16e-05	0.000248	CcSEcCtD
Eprosartan—Feeling abnormal—Docetaxel—prostate cancer	7.13e-05	0.000246	CcSEcCtD
Eprosartan—Diarrhoea—Etoposide—prostate cancer	7.12e-05	0.000246	CcSEcCtD
Eprosartan—Anorexia—Prednisone—prostate cancer	7.11e-05	0.000246	CcSEcCtD
Eprosartan—Tinnitus—Doxorubicin—prostate cancer	7.08e-05	0.000245	CcSEcCtD
Eprosartan—Gastrointestinal pain—Docetaxel—prostate cancer	7.07e-05	0.000244	CcSEcCtD
Eprosartan—Flatulence—Epirubicin—prostate cancer	7.04e-05	0.000243	CcSEcCtD
Eprosartan—Tension—Epirubicin—prostate cancer	7.01e-05	0.000242	CcSEcCtD
Eprosartan—Nervousness—Epirubicin—prostate cancer	6.94e-05	0.00024	CcSEcCtD
Eprosartan—Back pain—Epirubicin—prostate cancer	6.91e-05	0.000239	CcSEcCtD
Eprosartan—Feeling abnormal—Capecitabine—prostate cancer	6.9e-05	0.000239	CcSEcCtD
Eprosartan—Dizziness—Etoposide—prostate cancer	6.88e-05	0.000238	CcSEcCtD
Eprosartan—Muscle spasms—Epirubicin—prostate cancer	6.87e-05	0.000238	CcSEcCtD
Eprosartan—Gastrointestinal pain—Capecitabine—prostate cancer	6.85e-05	0.000237	CcSEcCtD
Eprosartan—Body temperature increased—Docetaxel—prostate cancer	6.84e-05	0.000236	CcSEcCtD
Eprosartan—Abdominal pain—Docetaxel—prostate cancer	6.84e-05	0.000236	CcSEcCtD
Eprosartan—Chills—Doxorubicin—prostate cancer	6.82e-05	0.000236	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Prednisone—prostate cancer	6.8e-05	0.000235	CcSEcCtD
Eprosartan—Insomnia—Prednisone—prostate cancer	6.75e-05	0.000233	CcSEcCtD
Eprosartan—Paraesthesia—Prednisone—prostate cancer	6.7e-05	0.000232	CcSEcCtD
Eprosartan—Urticaria—Capecitabine—prostate cancer	6.65e-05	0.00023	CcSEcCtD
Eprosartan—Ill-defined disorder—Epirubicin—prostate cancer	6.63e-05	0.000229	CcSEcCtD
Eprosartan—Abdominal pain—Capecitabine—prostate cancer	6.62e-05	0.000229	CcSEcCtD
Eprosartan—Body temperature increased—Capecitabine—prostate cancer	6.62e-05	0.000229	CcSEcCtD
Eprosartan—Vomiting—Etoposide—prostate cancer	6.62e-05	0.000229	CcSEcCtD
Eprosartan—Dyspepsia—Prednisone—prostate cancer	6.57e-05	0.000227	CcSEcCtD
Eprosartan—Rash—Etoposide—prostate cancer	6.56e-05	0.000227	CcSEcCtD
Eprosartan—Dermatitis—Etoposide—prostate cancer	6.56e-05	0.000227	CcSEcCtD
Eprosartan—Headache—Etoposide—prostate cancer	6.52e-05	0.000225	CcSEcCtD
Eprosartan—Flatulence—Doxorubicin—prostate cancer	6.52e-05	0.000225	CcSEcCtD
Eprosartan—Tension—Doxorubicin—prostate cancer	6.49e-05	0.000224	CcSEcCtD
Eprosartan—Decreased appetite—Prednisone—prostate cancer	6.48e-05	0.000224	CcSEcCtD
Eprosartan—Malaise—Epirubicin—prostate cancer	6.45e-05	0.000223	CcSEcCtD
Eprosartan—Fatigue—Prednisone—prostate cancer	6.43e-05	0.000222	CcSEcCtD
Eprosartan—Nervousness—Doxorubicin—prostate cancer	6.42e-05	0.000222	CcSEcCtD
Eprosartan—Vertigo—Epirubicin—prostate cancer	6.42e-05	0.000222	CcSEcCtD
Eprosartan—Syncope—Epirubicin—prostate cancer	6.41e-05	0.000222	CcSEcCtD
Eprosartan—Back pain—Doxorubicin—prostate cancer	6.4e-05	0.000221	CcSEcCtD
Eprosartan—Constipation—Prednisone—prostate cancer	6.38e-05	0.00022	CcSEcCtD
Eprosartan—Hypersensitivity—Docetaxel—prostate cancer	6.37e-05	0.00022	CcSEcCtD
Eprosartan—Muscle spasms—Doxorubicin—prostate cancer	6.36e-05	0.00022	CcSEcCtD
Eprosartan—Palpitations—Epirubicin—prostate cancer	6.32e-05	0.000218	CcSEcCtD
Eprosartan—Loss of consciousness—Epirubicin—prostate cancer	6.28e-05	0.000217	CcSEcCtD
Eprosartan—Cough—Epirubicin—prostate cancer	6.24e-05	0.000216	CcSEcCtD
Eprosartan—Asthenia—Docetaxel—prostate cancer	6.21e-05	0.000214	CcSEcCtD
Eprosartan—Nausea—Etoposide—prostate cancer	6.18e-05	0.000214	CcSEcCtD
Eprosartan—Hypersensitivity—Capecitabine—prostate cancer	6.17e-05	0.000213	CcSEcCtD
Eprosartan—Feeling abnormal—Prednisone—prostate cancer	6.15e-05	0.000212	CcSEcCtD
Eprosartan—Ill-defined disorder—Doxorubicin—prostate cancer	6.14e-05	0.000212	CcSEcCtD
Eprosartan—Pruritus—Docetaxel—prostate cancer	6.12e-05	0.000212	CcSEcCtD
Eprosartan—Gastrointestinal pain—Prednisone—prostate cancer	6.1e-05	0.000211	CcSEcCtD
Eprosartan—Chest pain—Epirubicin—prostate cancer	6.09e-05	0.00021	CcSEcCtD
Eprosartan—Arthralgia—Epirubicin—prostate cancer	6.09e-05	0.00021	CcSEcCtD
Eprosartan—Myalgia—Epirubicin—prostate cancer	6.09e-05	0.00021	CcSEcCtD
Eprosartan—Anxiety—Epirubicin—prostate cancer	6.06e-05	0.00021	CcSEcCtD
Eprosartan—Discomfort—Epirubicin—prostate cancer	6.01e-05	0.000208	CcSEcCtD
Eprosartan—Asthenia—Capecitabine—prostate cancer	6.01e-05	0.000208	CcSEcCtD
Eprosartan—Malaise—Doxorubicin—prostate cancer	5.96e-05	0.000206	CcSEcCtD
Eprosartan—Dry mouth—Epirubicin—prostate cancer	5.95e-05	0.000206	CcSEcCtD
Eprosartan—Vertigo—Doxorubicin—prostate cancer	5.94e-05	0.000205	CcSEcCtD
Eprosartan—Syncope—Doxorubicin—prostate cancer	5.93e-05	0.000205	CcSEcCtD
Eprosartan—Urticaria—Prednisone—prostate cancer	5.93e-05	0.000205	CcSEcCtD
Eprosartan—Pruritus—Capecitabine—prostate cancer	5.92e-05	0.000205	CcSEcCtD
Eprosartan—Diarrhoea—Docetaxel—prostate cancer	5.92e-05	0.000205	CcSEcCtD
Eprosartan—Abdominal pain—Prednisone—prostate cancer	5.9e-05	0.000204	CcSEcCtD
Eprosartan—Body temperature increased—Prednisone—prostate cancer	5.9e-05	0.000204	CcSEcCtD
Eprosartan—Palpitations—Doxorubicin—prostate cancer	5.84e-05	0.000202	CcSEcCtD
Eprosartan—Loss of consciousness—Doxorubicin—prostate cancer	5.81e-05	0.000201	CcSEcCtD
Eprosartan—Cough—Doxorubicin—prostate cancer	5.77e-05	0.000199	CcSEcCtD
Eprosartan—Shock—Epirubicin—prostate cancer	5.74e-05	0.000198	CcSEcCtD
Eprosartan—Diarrhoea—Capecitabine—prostate cancer	5.73e-05	0.000198	CcSEcCtD
Eprosartan—Dizziness—Docetaxel—prostate cancer	5.72e-05	0.000198	CcSEcCtD
Eprosartan—Thrombocytopenia—Epirubicin—prostate cancer	5.71e-05	0.000197	CcSEcCtD
Eprosartan—Tachycardia—Epirubicin—prostate cancer	5.69e-05	0.000197	CcSEcCtD
Eprosartan—Hyperhidrosis—Epirubicin—prostate cancer	5.64e-05	0.000195	CcSEcCtD
Eprosartan—Chest pain—Doxorubicin—prostate cancer	5.63e-05	0.000195	CcSEcCtD
Eprosartan—Arthralgia—Doxorubicin—prostate cancer	5.63e-05	0.000195	CcSEcCtD
Eprosartan—Myalgia—Doxorubicin—prostate cancer	5.63e-05	0.000195	CcSEcCtD
Eprosartan—Anxiety—Doxorubicin—prostate cancer	5.61e-05	0.000194	CcSEcCtD
Eprosartan—Discomfort—Doxorubicin—prostate cancer	5.56e-05	0.000192	CcSEcCtD
Eprosartan—Anorexia—Epirubicin—prostate cancer	5.56e-05	0.000192	CcSEcCtD
Eprosartan—Dizziness—Capecitabine—prostate cancer	5.54e-05	0.000191	CcSEcCtD
Eprosartan—Dry mouth—Doxorubicin—prostate cancer	5.51e-05	0.00019	CcSEcCtD
Eprosartan—Vomiting—Docetaxel—prostate cancer	5.5e-05	0.00019	CcSEcCtD
Eprosartan—Hypersensitivity—Prednisone—prostate cancer	5.5e-05	0.00019	CcSEcCtD
Eprosartan—Rash—Docetaxel—prostate cancer	5.45e-05	0.000189	CcSEcCtD
Eprosartan—Hypotension—Epirubicin—prostate cancer	5.45e-05	0.000188	CcSEcCtD
Eprosartan—Dermatitis—Docetaxel—prostate cancer	5.45e-05	0.000188	CcSEcCtD
Eprosartan—Headache—Docetaxel—prostate cancer	5.42e-05	0.000187	CcSEcCtD
Eprosartan—Asthenia—Prednisone—prostate cancer	5.35e-05	0.000185	CcSEcCtD
Eprosartan—Vomiting—Capecitabine—prostate cancer	5.32e-05	0.000184	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Epirubicin—prostate cancer	5.32e-05	0.000184	CcSEcCtD
Eprosartan—Shock—Doxorubicin—prostate cancer	5.31e-05	0.000184	CcSEcCtD
Eprosartan—Thrombocytopenia—Doxorubicin—prostate cancer	5.29e-05	0.000183	CcSEcCtD
Eprosartan—Rash—Capecitabine—prostate cancer	5.28e-05	0.000183	CcSEcCtD
Eprosartan—Pruritus—Prednisone—prostate cancer	5.28e-05	0.000182	CcSEcCtD
Eprosartan—Insomnia—Epirubicin—prostate cancer	5.28e-05	0.000182	CcSEcCtD
Eprosartan—Dermatitis—Capecitabine—prostate cancer	5.28e-05	0.000182	CcSEcCtD
Eprosartan—Tachycardia—Doxorubicin—prostate cancer	5.27e-05	0.000182	CcSEcCtD
Eprosartan—Headache—Capecitabine—prostate cancer	5.25e-05	0.000181	CcSEcCtD
Eprosartan—Paraesthesia—Epirubicin—prostate cancer	5.24e-05	0.000181	CcSEcCtD
Eprosartan—Hyperhidrosis—Doxorubicin—prostate cancer	5.22e-05	0.00018	CcSEcCtD
Eprosartan—Dyspnoea—Epirubicin—prostate cancer	5.2e-05	0.00018	CcSEcCtD
Eprosartan—Somnolence—Epirubicin—prostate cancer	5.19e-05	0.000179	CcSEcCtD
Eprosartan—Anorexia—Doxorubicin—prostate cancer	5.15e-05	0.000178	CcSEcCtD
Eprosartan—Nausea—Docetaxel—prostate cancer	5.14e-05	0.000178	CcSEcCtD
Eprosartan—Dyspepsia—Epirubicin—prostate cancer	5.14e-05	0.000178	CcSEcCtD
Eprosartan—Diarrhoea—Prednisone—prostate cancer	5.1e-05	0.000176	CcSEcCtD
Eprosartan—Decreased appetite—Epirubicin—prostate cancer	5.07e-05	0.000175	CcSEcCtD
Eprosartan—Hypotension—Doxorubicin—prostate cancer	5.04e-05	0.000174	CcSEcCtD
Eprosartan—Fatigue—Epirubicin—prostate cancer	5.03e-05	0.000174	CcSEcCtD
Eprosartan—Constipation—Epirubicin—prostate cancer	4.99e-05	0.000172	CcSEcCtD
Eprosartan—Pain—Epirubicin—prostate cancer	4.99e-05	0.000172	CcSEcCtD
Eprosartan—Nausea—Capecitabine—prostate cancer	4.97e-05	0.000172	CcSEcCtD
Eprosartan—Dizziness—Prednisone—prostate cancer	4.93e-05	0.00017	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Doxorubicin—prostate cancer	4.92e-05	0.00017	CcSEcCtD
Eprosartan—Insomnia—Doxorubicin—prostate cancer	4.88e-05	0.000169	CcSEcCtD
Eprosartan—Paraesthesia—Doxorubicin—prostate cancer	4.85e-05	0.000168	CcSEcCtD
Eprosartan—Dyspnoea—Doxorubicin—prostate cancer	4.81e-05	0.000166	CcSEcCtD
Eprosartan—Feeling abnormal—Epirubicin—prostate cancer	4.81e-05	0.000166	CcSEcCtD
Eprosartan—Somnolence—Doxorubicin—prostate cancer	4.8e-05	0.000166	CcSEcCtD
Eprosartan—Gastrointestinal pain—Epirubicin—prostate cancer	4.77e-05	0.000165	CcSEcCtD
Eprosartan—Dyspepsia—Doxorubicin—prostate cancer	4.75e-05	0.000164	CcSEcCtD
Eprosartan—Vomiting—Prednisone—prostate cancer	4.74e-05	0.000164	CcSEcCtD
Eprosartan—Rash—Prednisone—prostate cancer	4.7e-05	0.000163	CcSEcCtD
Eprosartan—Dermatitis—Prednisone—prostate cancer	4.7e-05	0.000162	CcSEcCtD
Eprosartan—Decreased appetite—Doxorubicin—prostate cancer	4.69e-05	0.000162	CcSEcCtD
Eprosartan—Headache—Prednisone—prostate cancer	4.67e-05	0.000162	CcSEcCtD
Eprosartan—Fatigue—Doxorubicin—prostate cancer	4.65e-05	0.000161	CcSEcCtD
Eprosartan—Urticaria—Epirubicin—prostate cancer	4.63e-05	0.00016	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—PLCB2—prostate cancer	4.63e-05	0.000464	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—LRP2—prostate cancer	4.63e-05	0.000464	CbGpPWpGaD
Eprosartan—Constipation—Doxorubicin—prostate cancer	4.62e-05	0.00016	CcSEcCtD
Eprosartan—Pain—Doxorubicin—prostate cancer	4.62e-05	0.00016	CcSEcCtD
Eprosartan—Body temperature increased—Epirubicin—prostate cancer	4.61e-05	0.000159	CcSEcCtD
Eprosartan—Abdominal pain—Epirubicin—prostate cancer	4.61e-05	0.000159	CcSEcCtD
Eprosartan—CYP2C9—Biological oxidations—GSTM1—prostate cancer	4.57e-05	0.000458	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—ADRB2—prostate cancer	4.57e-05	0.000458	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—P4HB—prostate cancer	4.54e-05	0.000455	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CX3CL1—prostate cancer	4.54e-05	0.000455	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—NCOA1—prostate cancer	4.53e-05	0.000454	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—GSTM1—prostate cancer	4.51e-05	0.000452	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—VAV3—prostate cancer	4.45e-05	0.000446	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HIST1H2BG—prostate cancer	4.45e-05	0.000446	CbGpPWpGaD
Eprosartan—Feeling abnormal—Doxorubicin—prostate cancer	4.45e-05	0.000154	CcSEcCtD
Eprosartan—Nausea—Prednisone—prostate cancer	4.43e-05	0.000153	CcSEcCtD
Eprosartan—Gastrointestinal pain—Doxorubicin—prostate cancer	4.41e-05	0.000153	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—PDE4D—prostate cancer	4.41e-05	0.000442	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—GRB7—prostate cancer	4.41e-05	0.000442	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—CYP1A1—prostate cancer	4.33e-05	0.000434	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—ITPR1—prostate cancer	4.32e-05	0.000433	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—RXRA—prostate cancer	4.31e-05	0.000432	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HIST1H4H—prostate cancer	4.3e-05	0.000431	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CXCL8—prostate cancer	4.3e-05	0.000431	CbGpPWpGaD
Eprosartan—Hypersensitivity—Epirubicin—prostate cancer	4.3e-05	0.000149	CcSEcCtD
Eprosartan—Urticaria—Doxorubicin—prostate cancer	4.29e-05	0.000148	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—prostate cancer	4.28e-05	0.000429	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HAO1—prostate cancer	4.27e-05	0.000428	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—CYP1A1—prostate cancer	4.27e-05	0.000428	CbGpPWpGaD
Eprosartan—Body temperature increased—Doxorubicin—prostate cancer	4.27e-05	0.000147	CcSEcCtD
Eprosartan—Abdominal pain—Doxorubicin—prostate cancer	4.27e-05	0.000147	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—GNG5—prostate cancer	4.2e-05	0.000421	CbGpPWpGaD
Eprosartan—Asthenia—Epirubicin—prostate cancer	4.19e-05	0.000145	CcSEcCtD
Eprosartan—Pruritus—Epirubicin—prostate cancer	4.13e-05	0.000143	CcSEcCtD
Eprosartan—Diarrhoea—Epirubicin—prostate cancer	3.99e-05	0.000138	CcSEcCtD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—HSD3B1—prostate cancer	3.99e-05	0.000399	CbGpPWpGaD
Eprosartan—Hypersensitivity—Doxorubicin—prostate cancer	3.98e-05	0.000137	CcSEcCtD
Eprosartan—Asthenia—Doxorubicin—prostate cancer	3.87e-05	0.000134	CcSEcCtD
Eprosartan—Dizziness—Epirubicin—prostate cancer	3.86e-05	0.000133	CcSEcCtD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—TBXAS1—prostate cancer	3.82e-05	0.000383	CbGpPWpGaD
Eprosartan—Pruritus—Doxorubicin—prostate cancer	3.82e-05	0.000132	CcSEcCtD
Eprosartan—Vomiting—Epirubicin—prostate cancer	3.71e-05	0.000128	CcSEcCtD
Eprosartan—Diarrhoea—Doxorubicin—prostate cancer	3.69e-05	0.000128	CcSEcCtD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ABCG5—prostate cancer	3.68e-05	0.000369	CbGpPWpGaD
Eprosartan—Rash—Epirubicin—prostate cancer	3.68e-05	0.000127	CcSEcCtD
Eprosartan—Dermatitis—Epirubicin—prostate cancer	3.67e-05	0.000127	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—TGFBR1—prostate cancer	3.66e-05	0.000366	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PTHLH—prostate cancer	3.66e-05	0.000366	CbGpPWpGaD
Eprosartan—Headache—Epirubicin—prostate cancer	3.65e-05	0.000126	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—AKR1C3—prostate cancer	3.6e-05	0.000361	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PRKACB—prostate cancer	3.58e-05	0.000359	CbGpPWpGaD
Eprosartan—Dizziness—Doxorubicin—prostate cancer	3.57e-05	0.000123	CcSEcCtD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—HSD3B2—prostate cancer	3.55e-05	0.000356	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PPP3CA—prostate cancer	3.49e-05	0.00035	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—THBS1—prostate cancer	3.49e-05	0.00035	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CBR1—prostate cancer	3.48e-05	0.000349	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CSAD—prostate cancer	3.48e-05	0.000349	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—TST—prostate cancer	3.48e-05	0.000349	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PSAT1—prostate cancer	3.48e-05	0.000349	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ADI1—prostate cancer	3.48e-05	0.000349	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GRHL1—prostate cancer	3.48e-05	0.000349	CbGpPWpGaD
Eprosartan—Nausea—Epirubicin—prostate cancer	3.47e-05	0.00012	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—ANXA1—prostate cancer	3.44e-05	0.000345	CbGpPWpGaD
Eprosartan—Vomiting—Doxorubicin—prostate cancer	3.43e-05	0.000119	CcSEcCtD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—LRP2—prostate cancer	3.41e-05	0.000341	CbGpPWpGaD
Eprosartan—Rash—Doxorubicin—prostate cancer	3.4e-05	0.000118	CcSEcCtD
Eprosartan—Dermatitis—Doxorubicin—prostate cancer	3.4e-05	0.000118	CcSEcCtD
Eprosartan—Headache—Doxorubicin—prostate cancer	3.38e-05	0.000117	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—PRKCZ—prostate cancer	3.37e-05	0.000338	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—P4HB—prostate cancer	3.34e-05	0.000335	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CG—prostate cancer	3.3e-05	0.000331	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—PPARA—prostate cancer	3.29e-05	0.00033	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FGFR4—prostate cancer	3.26e-05	0.000327	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PARP1—prostate cancer	3.26e-05	0.000327	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GRHPR—prostate cancer	3.24e-05	0.000325	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—UGT2B15—prostate cancer	3.24e-05	0.000325	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—UGT2B17—prostate cancer	3.24e-05	0.000325	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CKMT2—prostate cancer	3.24e-05	0.000325	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CALCA—prostate cancer	3.22e-05	0.000323	CbGpPWpGaD
Eprosartan—Nausea—Doxorubicin—prostate cancer	3.21e-05	0.000111	CcSEcCtD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—SULT2A1—prostate cancer	3.17e-05	0.000317	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CXCL12—prostate cancer	3.14e-05	0.000315	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—MED12—prostate cancer	3.12e-05	0.000312	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PGAM2—prostate cancer	3.05e-05	0.000305	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NAGLU—prostate cancer	3.05e-05	0.000305	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SULT2B1—prostate cancer	3.05e-05	0.000305	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTM3—prostate cancer	3.05e-05	0.000305	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—AOX1—prostate cancer	3.05e-05	0.000305	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—RFK—prostate cancer	3.05e-05	0.000305	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—MBTPS1—prostate cancer	3.05e-05	0.000305	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CG—prostate cancer	3e-05	0.0003	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—NCOA3—prostate cancer	2.98e-05	0.000298	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CASP9—prostate cancer	2.96e-05	0.000297	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CD—prostate cancer	2.9e-05	0.000291	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP3A43—prostate cancer	2.89e-05	0.000289	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—AMACR—prostate cancer	2.89e-05	0.000289	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NAT1—prostate cancer	2.89e-05	0.000289	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SRD5A2—prostate cancer	2.89e-05	0.000289	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—DEGS1—prostate cancer	2.89e-05	0.000289	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PRKCQ—prostate cancer	2.87e-05	0.000288	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NGFR—prostate cancer	2.87e-05	0.000288	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—prostate cancer	2.84e-05	0.000285	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MAP3K7—prostate cancer	2.84e-05	0.000284	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP2C19—prostate cancer	2.82e-05	0.000283	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HSD17B1—prostate cancer	2.75e-05	0.000276	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ACHE—prostate cancer	2.75e-05	0.000276	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FGF10—prostate cancer	2.73e-05	0.000273	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ADRB2—prostate cancer	2.7e-05	0.00027	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—JAK2—prostate cancer	2.66e-05	0.000267	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—MAP2K1—prostate cancer	2.65e-05	0.000266	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—prostate cancer	2.65e-05	0.000265	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PRKACB—prostate cancer	2.63e-05	0.000264	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CD—prostate cancer	2.63e-05	0.000264	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—VAV3—prostate cancer	2.63e-05	0.000264	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—CREBBP—prostate cancer	2.61e-05	0.000262	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP17A1—prostate cancer	2.61e-05	0.000261	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TGFBR2—prostate cancer	2.59e-05	0.00026	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ITPR1—prostate cancer	2.55e-05	0.000256	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CB—prostate cancer	2.53e-05	0.000253	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—NCOA2—prostate cancer	2.48e-05	0.000249	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—B4GALT4—prostate cancer	2.46e-05	0.000246	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HPGD—prostate cancer	2.46e-05	0.000246	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IGF1R—prostate cancer	2.44e-05	0.000245	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CXCL8—prostate cancer	2.43e-05	0.000243	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—JAK2—prostate cancer	2.42e-05	0.000242	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—LPL—prostate cancer	2.34e-05	0.000234	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—IL2—prostate cancer	2.32e-05	0.000233	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PDGFRB—prostate cancer	2.32e-05	0.000232	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—TNFRSF21—prostate cancer	2.31e-05	0.000231	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CB—prostate cancer	2.3e-05	0.00023	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ITGB3—prostate cancer	2.26e-05	0.000226	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP7B1—prostate cancer	2.25e-05	0.000225	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—MTAP—prostate cancer	2.25e-05	0.000225	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CXCL8—prostate cancer	2.21e-05	0.000221	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—prostate cancer	2.19e-05	0.00022	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ERBB3—prostate cancer	2.19e-05	0.00022	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SULT1E1—prostate cancer	2.19e-05	0.000219	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SRD5A1—prostate cancer	2.19e-05	0.000219	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FGFR2—prostate cancer	2.19e-05	0.000219	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—prostate cancer	2.13e-05	0.000213	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL2—prostate cancer	2.11e-05	0.000211	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TERT—prostate cancer	2.1e-05	0.00021	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—NCOA1—prostate cancer	2.09e-05	0.00021	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HSD17B3—prostate cancer	2.09e-05	0.000209	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ACSL4—prostate cancer	2.09e-05	0.000209	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—prostate cancer	2.06e-05	0.000207	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HIF1A—prostate cancer	2.01e-05	0.000201	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ARG2—prostate cancer	2e-05	0.000201	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—UMPS—prostate cancer	2e-05	0.000201	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PHGDH—prostate cancer	2e-05	0.000201	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—prostate cancer	1.99e-05	0.0002	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—LDHB—prostate cancer	1.96e-05	0.000197	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—LEP—prostate cancer	1.96e-05	0.000196	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CAV1—prostate cancer	1.94e-05	0.000195	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP3A5—prostate cancer	1.93e-05	0.000193	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KDR—prostate cancer	1.92e-05	0.000193	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ESR1—prostate cancer	1.87e-05	0.000188	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PDHA1—prostate cancer	1.86e-05	0.000186	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—TCN2—prostate cancer	1.86e-05	0.000186	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTA3—prostate cancer	1.86e-05	0.000186	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—UCP3—prostate cancer	1.86e-05	0.000186	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—BAD—prostate cancer	1.83e-05	0.000183	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HSD3B1—prostate cancer	1.78e-05	0.000178	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SLC22A3—prostate cancer	1.78e-05	0.000178	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—APC—prostate cancer	1.77e-05	0.000177	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CG—prostate cancer	1.77e-05	0.000177	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EGF—prostate cancer	1.75e-05	0.000175	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IRS1—prostate cancer	1.75e-05	0.000175	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—LPL—prostate cancer	1.72e-05	0.000173	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—TBXAS1—prostate cancer	1.7e-05	0.000171	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTA4—prostate cancer	1.7e-05	0.000171	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—GSK3B—prostate cancer	1.7e-05	0.00017	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—INS—prostate cancer	1.68e-05	0.000168	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	1.66e-05	0.000167	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTA2—prostate cancer	1.66e-05	0.000166	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CREBBP—prostate cancer	1.64e-05	0.000164	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ABCG5—prostate cancer	1.64e-05	0.000164	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SULT1A1—prostate cancer	1.64e-05	0.000164	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IGF1—prostate cancer	1.62e-05	0.000162	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—EGFR—prostate cancer	1.61e-05	0.000162	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTA1—prostate cancer	1.6e-05	0.00016	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NAT2—prostate cancer	1.58e-05	0.000159	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTO1—prostate cancer	1.58e-05	0.000159	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HSD3B2—prostate cancer	1.58e-05	0.000159	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MAP2K1—prostate cancer	1.57e-05	0.000157	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CD—prostate cancer	1.56e-05	0.000156	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CA—prostate cancer	1.54e-05	0.000154	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SERPINE1—prostate cancer	1.54e-05	0.000154	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—KRAS—prostate cancer	1.52e-05	0.000153	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	1.52e-05	0.000152	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PLCB2—prostate cancer	1.52e-05	0.000152	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—LRP2—prostate cancer	1.52e-05	0.000152	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP2C18—prostate cancer	1.52e-05	0.000152	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FGF2—prostate cancer	1.49e-05	0.000149	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—P4HB—prostate cancer	1.49e-05	0.000149	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NOS3—prostate cancer	1.47e-05	0.000147	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SLC22A1—prostate cancer	1.45e-05	0.000145	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	1.43e-05	0.000143	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—JAK2—prostate cancer	1.43e-05	0.000143	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SULT2A1—prostate cancer	1.41e-05	0.000141	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CA—prostate cancer	1.4e-05	0.00014	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MDM2—prostate cancer	1.39e-05	0.00014	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—MED12—prostate cancer	1.39e-05	0.000139	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GNG5—prostate cancer	1.38e-05	0.000138	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ERBB2—prostate cancer	1.37e-05	0.000138	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CB—prostate cancer	1.36e-05	0.000136	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NCOA3—prostate cancer	1.33e-05	0.000133	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CXCL8—prostate cancer	1.3e-05	0.000131	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	1.3e-05	0.000131	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CDKN1B—prostate cancer	1.27e-05	0.000128	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HPGDS—prostate cancer	1.26e-05	0.000127	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—AKT1—prostate cancer	1.26e-05	0.000126	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP2C19—prostate cancer	1.26e-05	0.000126	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CASP3—prostate cancer	1.25e-05	0.000125	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL2—prostate cancer	1.25e-05	0.000125	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL6—prostate cancer	1.24e-05	0.000124	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ACHE—prostate cancer	1.23e-05	0.000123	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTT1—prostate cancer	1.23e-05	0.000123	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCND1—prostate cancer	1.21e-05	0.000122	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP2A6—prostate cancer	1.21e-05	0.000122	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	1.21e-05	0.000121	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CTNNB1—prostate cancer	1.2e-05	0.00012	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—AKR1C3—prostate cancer	1.18e-05	0.000118	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MMP9—prostate cancer	1.18e-05	0.000118	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CDKN1A—prostate cancer	1.17e-05	0.000118	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PRKACB—prostate cancer	1.17e-05	0.000118	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PTEN—prostate cancer	1.17e-05	0.000117	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP17A1—prostate cancer	1.16e-05	0.000116	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.15e-05	0.000115	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—AKT1—prostate cancer	1.14e-05	0.000115	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EP300—prostate cancer	1.12e-05	0.000112	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NCOA2—prostate cancer	1.11e-05	0.000111	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SRC—prostate cancer	1.09e-05	0.000109	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—VEGFA—prostate cancer	1.06e-05	0.000106	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SLC5A5—prostate cancer	1.06e-05	0.000106	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—STAT3—prostate cancer	1.05e-05	0.000105	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP2E1—prostate cancer	1.03e-05	0.000103	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NQO1—prostate cancer	1.02e-05	0.000102	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—TH—prostate cancer	1e-05	0.000101	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	9.98e-06	0.0001	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP3A4—prostate cancer	9.94e-06	9.96e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	9.89e-06	9.91e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP1B1—prostate cancer	9.77e-06	9.8e-05	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MYC—prostate cancer	9.74e-06	9.76e-05	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TGFB1—prostate cancer	9.71e-06	9.73e-05	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EGFR—prostate cancer	9.52e-06	9.54e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GGT1—prostate cancer	9.47e-06	9.49e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NCOA1—prostate cancer	9.32e-06	9.34e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP19A1—prostate cancer	9.19e-06	9.21e-05	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KRAS—prostate cancer	9e-06	9.02e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—RXRA—prostate cancer	8.87e-06	8.89e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	8.63e-06	8.65e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—COMT—prostate cancer	8.54e-06	8.56e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTP1—prostate cancer	8.5e-06	8.52e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ITPR1—prostate cancer	8.37e-06	8.39e-05	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CA—prostate cancer	8.27e-06	8.28e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	8.23e-06	8.24e-05	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TP53—prostate cancer	8e-06	8.01e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—TYMS—prostate cancer	7.91e-06	7.92e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTM1—prostate cancer	7.81e-06	7.83e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—LPL—prostate cancer	7.67e-06	7.69e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP1A1—prostate cancer	7.41e-06	7.42e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ERCC2—prostate cancer	7.35e-06	7.36e-05	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL6—prostate cancer	7.32e-06	7.34e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—MTHFR—prostate cancer	6.91e-06	6.92e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PPARA—prostate cancer	6.78e-06	6.79e-05	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—AKT1—prostate cancer	6.75e-06	6.77e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CAV1—prostate cancer	6.37e-06	6.38e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	6.09e-06	6.1e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CG—prostate cancer	5.8e-06	5.81e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—INS—prostate cancer	5.49e-06	5.5e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CREBBP—prostate cancer	5.38e-06	5.39e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CD—prostate cancer	5.1e-06	5.11e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NOS3—prostate cancer	4.82e-06	4.83e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CB—prostate cancer	4.45e-06	4.46e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTGS2—prostate cancer	4.41e-06	4.41e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTEN—prostate cancer	3.84e-06	3.85e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—EP300—prostate cancer	3.66e-06	3.67e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CA—prostate cancer	2.71e-06	2.72e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—AKT1—prostate cancer	2.21e-06	2.22e-05	CbGpPWpGaD
